Gulf International Bank UK Ltd Has $2.30 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gulf International Bank UK Ltd lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,754 shares of the biopharmaceutical company’s stock after selling 99 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Alnylam Pharmaceuticals were worth $2,295,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $42,000. Finally, True Wealth Design LLC increased its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,752 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the transaction, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock worth $20,397,849 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on ALNY shares. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Barclays lifted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Raymond James lifted their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, HC Wainwright lifted their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Stock Up 4.1 %

NASDAQ ALNY opened at $246.75 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a 50 day moving average of $254.30 and a 200-day moving average of $262.42. The company has a market cap of $31.94 billion, a price-to-earnings ratio of -113.71 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.